Article Information
History
- October 25, 2024.
Article Versions
- Version 1 (October 24, 2024 - 12:37).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Friedemann Schad1,7 (fschad{at}havelhoehe.de),
- Anja Thronicke2,
- Ralf-Diether Hofheinz3,
- Reinhild Klein4,
- Patricia Grabowski5,
- Shiao Li Oei2,
- Hannah Wuestefeld6 and
- Christian Grah6
- 1 Hospital Havelhoehe, Interdisciplinary Oncological Centre, Kladower Damm 221, 14089 Berlin, Germany and Research Institute Havelhoehe, Network Oncology Registry, Kladower Damm 221, 14089 Berlin, Germany;
- 2 Research Institute Havelhoehe, Network Oncology Registry, Kladower Damm 221, 14089 Berlin, Germany;
- 3 Mannheim University Hospital, Mannheim Cancer Center, Theodor-Kutzer Ufer 1-3, 68167 Mannheim, Germany;
- 4 University Hospital Tuebingen, Department of Internal Medicine II, Otfried-Mueller Strasse 10, 72076 Tuebingen, Germany;
- 5 Hospital Havelhoehe, Interdisciplinary Oncological Centre, Kladower Damm 221, 14089 Berlin, Germany and Charite Universitaetsmedizin Berlin, Charite Fatigue Centrum, Augustenburger Platz 1, 13353 Berlin Germany;
- 6 Hospital Havelhoehe, Lung Cancer Center, Kladower Damm 221, 14089 Berlin, Germany
- ↵* Corresponding author; email: fschad{at}havelhoehe.de
Posted October 25, 2024.
PD-1/PD-L1 Blockade Combined with AbnobaViscum® Therapy is Linked to Improved Survival in Advanced or Metastatic NSCLC Patients, an ESMO-GROW Related Real-World Data Registry Study
